Clinical trials

CETF is the sole or primary sponsor of all trials listed below, unless noted.

Participating in an outpatient clinical trial is one of the best ways to access potentially lifesaving treatments for COVID-19. CETF sponsored clinical trials focus on repurposed drugs already proven to be safe, so the risks to participants are minimal. It’s also a meaningful way to support the fight against COVID-19 by helping researchers identify treatments that will help others avoid hospitalization and save lives. Please see our list of ongoing clinical trials to find one near you.  

CETF supported clinical trials

Drug
Description
Investigator
Institution
Location
Support type
CETF Approved Grant Amount
Trial Start Date
Status
Camostat mesylate
Description
Treatment given early post-infection
Investigator
Ole Schmeltz Søgaard
Institution
Aarhus University
Location
Denmark
Support type
• Grant
• Fundraising
• Trial Awareness
CETF Grant amount
$100K
Trial start date
April 25, 2020
pending
Status
Recruiting
Description
Treatment given early post-infection
Investigator
Joseph Vinetz
Institution
Yale School of Medicine
Location
New Haven, CT
Support type
• Grant
• Fundraising
• Trial Awareness
CETF Grant amount
$600K
Trial start date
May 11, 2020
pending
Status
Approved
Description
Treatment given early post-infection
Investigator
Joseph Vinetz
Institution
Location
Arizona
Support type
• Grant
• Fundraising
• Trial Awareness
CETF Grant amount
Trial start date
pending
Status
Planning
Description
Treatment given early post-infection
Investigator
Joseph Vinetz
Institution
Location
Texas
Support type
• Grant
• Fundraising
• Trial Awareness
CETF Grant amount
Trial start date
pending
Status
Planning
Interferon Lambda
Description
Pre-and post-exposure outpatient treatment of family members
Investigator
Mark Sulkowski
Institution
Johns Hopkins University
Location
Baltimore, MD
Support type
• Grant
• Fundraising
• Trial Awareness
CETF Grant amount
$325K
Trial start date
May 29, 2020
pending
Status
Planning
Description
Recently admitted with mild symptoms
Investigator
Raymond Chung
Institution
Mass General Hospital
Location
Boston, MA
Support type
• Grant
• Fundraising
• Trial Awareness
CETF Grant amount
$146K
Trial start date
May 24, 2020
pending
Status
Planning
Description
Recently admitted patients
Investigator
Thomas Marron
Institution
Mount Sinai Hospital
Location
New York, NY
Support type
• Grant
• Fundraising
• Trial Awareness
CETF Grant amount
$400K
Trial start date
May 9, 2020
pending
Status
Recruiting
Description
Outpatient treatment
Investigator
Prasanna Jagannathan
Institution
Stanford
Location
Palo Alto, CA
Support type
• Grant
• Fundraising
• Trial Awareness
CETF Grant amount
Trial start date
May 10, 2020
pending
Status
Recruiting
Favipiravir
Description
Favipiravir early post-infection
Investigator
Noah Federman
Institution
UCLA
Location
Los Angeles, CA
Support type
• Grant
• Fundraising
• Trial Awareness
CETF Grant amount
$250K
Trial start date
pending
Status
Planning
Doxazosin
Description
Doxazosin early post-infection
Investigator
Chetan Bettegowda
Institution
Johns Hopkins
Location
Baltimore, MD
Support type
• Grant
• Fundraising
• Trial Awareness
CETF Grant amount
$500K
Trial start date
pending
Status
Planning
Monoclonal antibodies
Description
Infuse post-infection
Investigator
Michel Nussenzweig
Institution
Rockefeller University
Location
New York, NY
Support type
• Grant
• Fundraising
• Trial Awareness
CETF Grant amount
$500K
Trial start date
pending
Status
Planning
Fluvoxamine
Description
Early post-infection
Investigator
Dr. Eric Lenze
Institution
Washington University in St. Louis
Location
St Louis, MO
Support type
• Grant
• Fundraising
• Trial Awareness
CETF Grant amount
$66,276.99
Trial start date
April 10, 2020
pending
Status
Completed

Other outpatient clinical trials (partial list)

Remdesivir
Leronlimab
Interferon beta
Niclosamide
EIDD-2801
learn more about the most promising drugs ›
Donate to the
COVID-19 Early Treatment Fund today
Donate